Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jana‐Maria Schneidewind"'
Publikováno v:
Artificial Organs. 17:775-781
The neutralization of bacterial endotoxins (ET) is still an unsolved problem in therapeutic medicine. The efficacy of antiendotoxin antibodies or receptor antagonists and other substances interferring with the endotoxininduced pathomechanisms is depe
Autor:
Roland E. Winkler, F. Loth, E. Behm, Dieter Falkenhagen, T. Möhrke, Gail S. Brown, Jana-Maria Schneidewind, Michaela Palm, S. Mietzner, Horst Klinkmann, Holtz M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82425e03928509d239a0a96fd2a9414
https://doi.org/10.1159/000418274
https://doi.org/10.1159/000418274
Autor:
Doris Lange, Wolfgang Ramlow, Jana-Maria Schneidewind-Mueller, Nobuhito Kashiwagi, Helmut Soerensen, Takashi Yokoyama, Marita Franz
Publikováno v:
Rheumatology International. 26:409-415
The aim of this study is to investigate the clinical effects of cytapheresis using the Adacolumn system (selective removal of circulating monocytes and granulocytes by means of an extracorporeal type column) in patients with active systemic lupus ery
Autor:
Roland E. Winkler, Waltraud Müller, Wolfgang Ramlow, Michael Tiess, Jana‐Maria Schneidewind‐Müller
Publikováno v:
Artificial Organs. 26:140-144
The success of apheresis treatment is often measured as a decrease in the detected antibodies and an improvement in different disease-related scores. Sometimes, however, the seriousness of the disease does not correlate with the antibody level. Durin
Publikováno v:
ASAIO Journal. 45:397-407
The objective of this multicenter trial, which included 28 clinical centers, was to determine if repeated low density lipoprotein (LDL)-apheresis using the Liposorber LA-15 system (Kaneka Corporation, Osaka, Japan) could lead to an additional acute a
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 7(2)
Vascular catheters have become essential tools for management of hospitalized or chronically ill patients requiring intensive medical treatments such as extracorporeal detoxification procedures. The increased use of such devices has been accompanied
Autor:
Waltraud Müller, Wolfgang Ramlow, Michael Tiess, Jana Maria Schneidewind, Ann Michelsen, Goran Matic, Doris Hofmann, Roland E. Winkler
Publikováno v:
Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis. 5(1)
Wegener's granulomatosis is a vasculitic disease predominantly affecting the upper respiratory tract, lungs, and kidneys. Three patients with Wegener's granulomatosis and rapidly progressive glomerulonephritis were treated with an intensified regimen
Autor:
Pedro Mestres, Reinhard Latza, Ralf Schiel, Piran Sioshansi, Silke Bambauer, Jana Maria Schneidewind, Rolf Bambauer
Publikováno v:
Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis. 4(5)
Infection, thrombosis, and stenosis are among the most frequent complications associated with blood contacting catheters. Because these problems are usually related to surface properties of the base catheter material, surface treatment processes such
Autor:
Eva‐Maria Kinze, Waltraud Müller, Wolfgang Ramlow, Michael Tiess, Goran Matic, Doris Hofmann, Gabi Hebestreit, Roland E. Winkler, Martin Keysser, Ann Michelsen, Jana‐Maria Schneidewind
Publikováno v:
Artificial organs. 24(2)
Elimination of IgG can be achieved by extracorporeal immunoadsorption (IA) based on specific binding to either staphylococcal protein A (Excorim) or sheep polyclonal antibodies directed against human IgG (Therasorb). In 602 analyzed sessions of IA, e
Publikováno v:
ASAIO journal (American Society for Artificial Internal Organs : 1992). 45(5)
In 34 patients (18 women, 16 men) suffering from familial hypercholesterolemia resistant to diet and lipid lowering drugs, low density lipoprotein (LDL) apheresis was performed during 72.8 + 43.2 months. Four different systems (Liposorber, 28 of 34,